Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
According to Acasti Pharma Inc.'s latest financial reports the company's current earnings (TTM) are $-14,630,000. The earnings displayed on this page is the company's Pretax Income.
Year | Income Before Tax | Net Income |
---|---|---|
2023 | $-14,630,000 | $-12,853,000 |
2022 | $-51,971,000 | $-42,429,000 |
2021 | $-10,467,000 | $-9,819,000 |
2020 | $-19,678,000 | $-19,678,000 |
2019 | $-25,513,000 | $-25,760,000 |
2018 | $-38,620,431 | $-43,861,594 |
2017 | $-16,651,567 | $-16,942,722 |
2016 | $ | $ |
2015 | $-4,661,416 | $-4,661,416 |
2014 | $-1,322,541 | $-1,322,541 |
2013 | $-10,435,936 | $-10,435,936 |
2012 | $-6,732,464 | $-6,732,464 |
2011 | $-6,538,661 | $-6,538,661 |
2010 | $ | $-2,426,846 |
2009 | $-1,527,334 | $-1,508,303 |